硼替佐米治疗复发性与难治性多发性骨髓瘤疗效及不良反应分析

摘要

Objective To investigate the clinical effects and adverse reactions of bortezomib in treatment of recurrent, refractory multiple myeloma. Methods 72 cases of recurrence, in our hospital in 2010 February-2015 year in February admitted to the re-fractory multiple myeloma patients, randomly divided into the treatment group and the control group, the treatment group by borte-zomib combined with dexamethasone treatment, while the control group treated by conventional methods, analysis and clinical ad-verse reactions the effect of. Results In the control group, the total clinical effective rate was 66.7%, while the treatment group the total clinical effective rate was 80.6%. Among them, the type of adverse reactions such as diarrhea, fatigue, nausea and anorexia, peripheral neuritis, herpes zoster and pneumonia. Conclusion Bortezomib treatment of relapsed, refractory multiple myeloma has very significant clinical effect, safe and reliable .%目的：探讨分析硼替佐米治疗复发、难治性多发性骨髓瘤的临床效果与不良反应。方法整群选择该院2010年2月—2015年2月收治的72例复发、难治性多发性骨髓瘤患者，随机的将其分成对照组和治疗组，其中治疗组采用硼替佐米结合地塞米松的方法治疗，而对照组采用常规方法治疗，分析临床疗效与不良反应的发生情况。结果对照组临床总有效率为66.7%；而治疗组临床总有效率为80.6%，其中治疗组的临床疗效明显的比对照组好，差异有统计学意义(P<0.05)。其中，发生不良反应的类型主要有腹泻、乏力、恶心与厌食、周围神经炎、带状疱疹与肺炎等。结论硼替佐米治疗复发、难治性多发性骨髓瘤具有非常显著的临床效果，安全可靠。